Literature DB >> 7923885

Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa.

C Christopoulos1.   

Abstract

Platelet surface immunoglobulin G (PSIgG) was measured ex vivo in nine patients with stable angina pectoris receiving continuous (48-96 h) infusions of Fab fragments of a chimaeric MoAb (human IgG with murine variable regions) to platelet glycoprotein IIb-IIIa. PSIgG was measured using flow cytometry (FC) and an Fc-specific anti-IgG polyclonal antibody, which did not cross-react with the chimaeric Fab fragment (c7E3-Fab). A variable but statistically significant (P < 0.05) elevation of PSIgG was present within 24 h after the onset of the infusion, and was more marked (P < 0.01) several days after the end of the infusion despite an exponential fall in platelet surface c7E3-Fab post-infusion. PSIgG returned to normal within 2 weeks after the end of the infusion. The timing of IgG recruitment to the platelet surface suggested the pre-existence in the patients' plasma of IgG binding to c7E3-Fab-bearing platelets. None of the patients developed thrombocytopenia. In order to assess the incidence of IgG bindable to c7E3-Fab-bearing platelets in controls clinically comparable to the c7E3-Fab infusion patients, normal platelets coated with either chimaeric (c) or murine (m) 7E3-Fab were incubated with plasmas from 21 patients with ischaemic heart disease, and recruitment of IgG to the platelet surface was measured by FC. Fourteen of the 21 plasmas contained IgG bindable to c7E3-Fab-coated platelets, whereas only one of the 21 plasmas contained IgG bindable to m7E3-Fab-coated platelets (a highly significant difference, P < 0.001). These findings indicate that infusions of Fab fragments of the chimaeric anti-platelet antibody 7E3 are often associated with elevations in PSIgG, which are probably due to pre-existing 'naturally occurring' antibodies to the Fab fragments of chimaeric (but not murine) 7E3, and most probably other chimaeric MoAbs. The possible clinical significance of such ex vivo measured activities is at present a matter for speculation, and requires further study.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923885      PMCID: PMC1534164          DOI: 10.1111/j.1365-2249.1994.tb06598.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Anti-gamma-globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies.

Authors:  C K OSTERLAND; M HARBOE; H G KUNKEL
Journal:  Vox Sang       Date:  1963 Mar-Apr       Impact factor: 2.144

2.  Platelet inhibition with an antibody to glycoprotein IIb/IIIa.

Authors:  D J Fitzgerald
Journal:  Circulation       Date:  1989-12       Impact factor: 29.690

3.  Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb-IIIa complex receptor.

Authors:  B S Coller; E I Peerschke; U Seligsohn; L E Scudder; A T Nurden; J P Rosa
Journal:  J Lab Clin Med       Date:  1986-04

4.  Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.

Authors:  S R Hanson; F I Pareti; Z M Ruggeri; U M Marzec; T J Kunicki; R R Montgomery; T S Zimmerman; L A Harker
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

5.  Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.

Authors:  H K Gold; L W Gimple; T Yasuda; R C Leinbach; W Werner; R Holt; R Jordan; H Berger; D Collen; B S Coller
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

6.  Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease.

Authors:  G Schuler; R Hambrecht; G Schlierf; J Niebauer; K Hauer; J Neumann; E Hoberg; A Drinkmann; F Bacher; M Grunze
Journal:  Circulation       Date:  1992-07       Impact factor: 29.690

7.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

Authors:  A F LoBuglio; R H Wheeler; J Trang; A Haynes; K Rogers; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

8.  Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.

Authors:  M L Simoons; M J de Boer; M J van den Brand; A J van Miltenburg; J C Hoorntje; G R Heyndrickx; L R van der Wieken; D de Bono; W Rutsch; T F Schaible
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

9.  A flow-cytometric approach to quantitative estimation of platelet surface immunoglobulin G.

Authors:  C G Christopoulos; H C Kelsey; S J Machin
Journal:  Vox Sang       Date:  1993       Impact factor: 2.144

10.  Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides.

Authors:  S J Knox; R Levy; S Hodgkinson; R Bell; S Brown; G S Wood; R Hoppe; E A Abel; L Steinman; R G Berger
Journal:  Blood       Date:  1991-01-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.